Hengrui, Braveheart Report Positive 52-Week Data For Heart Disease Drug HRS/BHB-1893
Jiangsu Hengrui Pharmaceuticals (1276.HK) and Braveheart Bio (BRVE) reported positive 52-week data for HRS/BHB-1893 in oHCM patients, showing improved exercise capacity and quality of life. The drug was well-tolerated, with no serious adverse events. Braveheart plans a Phase 2b study. 1276.HK closed at HKD 50.950, BRVE at $18.60.
How this was made
The 30-second read
Why it matters
The data suggest meaningful clinical benefit and a clear development path, likely prompting re‑rating by analysts and potential inflows from specialty‑focused investors.
Market read
First‑time release of extended trial results for a heart‑disease drug, a material catalyst for both tickers and potentially for the broader cardiology biotech sector.
What to watch
Regulatory timelines and the need for larger pivotal trials may temper near‑term price moves.
Background
The article reports the first public disclosure of 52‑week extension data for HRS/BHB‑1893, a novel therapy for obstructive hypertrophic cardiomyopathy, presented at the AHA Scientific Sessions 2026.
Ticker impact
Braveheart Bio presented the same 52‑week data and announced plans for a Phase 2b study, indicating continued development momentum.
likely upward pressure as investors anticipate further clinical progress
First public release of extended trial outcomes for Braveheart's lead candidate, a key catalyst for the US‑listed biotech.
Market effects
Positive cardiology data may lift sentiment across biotech firms developing heart‑failure therapies.
Hong Kong and US biotech markets could see modest gains from the news.
The trial results add to the pipeline narrative for cardiovascular drug developers worldwide.
Counterpoint
If longer‑term safety concerns emerge, the initial enthusiasm could fade, leading to a sell‑off.
Key entities
- companyJiangsu Hengrui Pharmaceuticals Co.Ltd
Hong Kong‑listed pharmaceutical company reporting the trial data.
- companyBraveheart Bio, Inc.
US‑listed biotech presenting the same data and planning a Phase 2b trial.
